News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Why AstraZeneca Stock Got Thumped on Thursday
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
The Pharma Letter9h
AstraZeneca in talks with Summit for over $15 billion license deal
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
The Manila Times on MSN3h
AstraZeneca eyes licensing lung cancer drug
ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
Stocks fade as tariff deadline looms large
Stocks fade as tariff deadline looms large - US President Donald Trump said he plans to start sending letters informing ...